SASadegh Abadijou

Sadegh Abadijou

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Sadegh Abadijou has a total of 14 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    FPL: False Positive Loss

    by Ali Akbar Kiaei, Mahnaz Boush, Danial Safaei, Sadegh Abadijou, Nima Baselizadeh, Ali Fayzi, Reza Bahadori, Nader Salari

    When training deep neural networks tasks, the most popular choices are cross-entropy loss. On the other hand, in general speaking, a decent loss function can take on shapes that are considerably more flexible and ought to be adapted for different activities and datasets. In most of the classification tasks, generally if the true class is not correctly recognized by the network (top1), that class is placed among the five classes with the highest probability (top5). This shows that the network does not necessarily recognize the correct class with a low probability, but a class similar to it (such as 3 vs. 8 in mnist) assigns a higher probability and this causes a mistake in that task. Accordingly, we proposed a loss function deals with the error of class that the neural network incorrectly recognized as correct, in addition to the correct class error. We call our proposed loss as False Positive Loss (FPL), with the intention of viewing and designing loss functions not only through the utilization of true class but also through the utilization of the value of false positive classes. One of the core properties of our proposed loss is full adaptability, which makes False Positive Loss be fully capable of getting reformulated by using other widely used loss functions formulas based on the task or the need of the users. Extensive experimental results demonstrate that our suggested loss function outperforms other well-known losses on a variety of tasks and datasets. As can be observed, the performance of our False Positive Loss is superior to that of the cross-entropy loss when it comes to tasks involving 2D picture classification. We have compared our loss with cross entropy as the most common classification loss function on some models (such as ResNet-18, ResNet-50 and Efficientnet-V2) through classification known as a basic computer vision task. with both random or pre-trained initial weights. As a result, in some cases the models with our loss outperform the same tasks with cross entropy from the viewpoint of some metric (i.e. accuracy and FP). For example, the resnet-50 on cifar-10 dataset with random initialization indicated a top1 accuracy of 94.93 with cross entropy and 95.25 with our loss, while for top5 accuracy the results are 99.86 and 99.87, respectively.


  • Open Access

    Active Identity Function as Activation Function

    by Ali Akbar Kiaei, Mahnaz Boush, Danial Safaei, Sadegh Abadijou, Nima Baselizadeh, Nader Salari, Masoud Mohammadi

    Selecting the optimal activation function for training deep neural networks has always been challenging because it significantly impacts the neural network’s performance and training speed. At this point, researchers are more likely to employ RELU than other well-known activation functions. After RELU, researchers have proposed many activation functions to improve RELU. None of them was capable of surpassing RELU as their most significant rival. SWISH outperformed RELU in several challenging experiments like classification, object detection, and tracking. Replacing RELU units with SWISH, which improves performance in many tasks. This paper proposed a new activation function surpassing Google’s brain’s SWISH function, Which we named AIF. Experiments indicate that our proposed activation function outperforms SWISH in various tasks.


  • Open Access

    Recommending Drug Combinations Using Reinforcement Learning targeting Genes/proteins associated with Heterozygous Familial Hypercholesterolemia: A comprehensive Systematic Review and Net-work Meta-analysis

    by Ali A. Kiaei, Mahnaz Boush, Sadegh Abadijou, Saeb Momeni, Danial Safaei, Reza Bahadori, Nader Salari, Masoud Mohammadi

    Background: Familial Hypercholesterolemia (FH) is a genetic disorder in lipoprotein metabolism caused by mutations that increase LDL and total cholesterol levels. High LDL and cholesterol levels increase atherosclerosis risk. FH mutations impact the LDL receptor (LDLR) gene, apolipoprotein B, and PCSK9. About 20% of FH cases have a polygenic basis that affects LDL levels. We decided to conduct a systematic review of the available research in this field to provide a thorough genes/proteins network meta-analysis on the impact of drug combinations on the management of heterozygous Familial Hypercholesterolemia (HeFH). This paper reviews and analyzes the literature on the effects of medication combinations on HeFH management. This study investigates articles that analyzed the management and adjuvants of HeFH to recommend forceful drug combinations. Methods: This systematic review and network meta-analysis analyzed the Science Direct, Embase, Scopus, PubMed, Web of Science (ISI), and Google Scholar databases without a lower time limit and up to July 2022. The current study consists of three fundamental stages. Firstly, drug combinations are recommended by reinforcement learning. In the second stage, we used a systematic review to analyze RL's outcomes in diverse populations (with a variety of ages, sex, etc.). Natural Language Processing (NLP) employs context to search these articles. We contrasted manual and NLP-based searches and discovered that NLP could find articles based on MeSH, not simply words. In stage three, we analyze RL outcomes using network meta-analysis. Results: This study uses the RAIN method to investigate the most effective medication combination for managing Heterozygous Familial Hypercholesterolemia (HeFH). Results from the method indicate that the best-recommended scenario is 2.7 times more efficient than the prescription of Ezetimibe as the initial scenario. Conclusion: Our systematic review and network meta-analysis review indicate that a drug combination of Ezetimibe, Pravastatin, and Simvastatin is highly effective. However, additional high-quality clinical trials are required to determine the efficacy and safety of other treatments.


  • 3DLaneNAS: Neural Architecture Search for Accurate and Light-Weight 3D Lane Detection

    by Ali Zoljodi, Mohammad Loni, Sadegh Abadijou, Mina Alibeigi, Masoud Daneshtalab